MAIA Quote, Financials, Valuation and Earnings

Johnson & Johnson has a net margin of -- compared to MAIA Biotechnology's net margin of 23.32%. MAIA Biotechnology's return on equity of -- beat Johnson & Johnson's return on equity of 30.18%.

MAIA Biotechnology has a consensus price target of $12.14, signalling upside risk potential of 581.74%. On the other hand Johnson & Johnson has an analysts' consensus of $173.66 which suggests that it could grow by 6.55%. Given that MAIA Biotechnology has higher upside potential than Johnson & Johnson, analysts believe MAIA Biotechnology is more attractive than Johnson & Johnson.

MAIA Biotechnology has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Johnson & Johnson has a beta of 0.414, suggesting its less volatile than the S&P 500 by 58.579%.

MAIA Biotechnology has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Johnson & Johnson offers a yield of 3.08% to investors and pays a quarterly dividend of $1.30 per share. MAIA Biotechnology pays -- of its earnings as a dividend. Johnson & Johnson pays out 84.05% of its earnings as a dividend. Johnson & Johnson's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

MAIA Biotechnology quarterly revenues are --, which are smaller than Johnson & Johnson quarterly revenues of $23.7B. MAIA Biotechnology's net income of -$4.5M is lower than Johnson & Johnson's net income of $5.5B. Notably, MAIA Biotechnology's price-to-earnings ratio is -- while Johnson & Johnson's PE ratio is 17.43x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for MAIA Biotechnology is -- versus 4.36x for Johnson & Johnson. Usually stocks with elevated PS ratios are considered overvalued.

Eli Lilly and has a net margin of -- compared to MAIA Biotechnology's net margin of 21.68%. MAIA Biotechnology's return on equity of -- beat Eli Lilly and's return on equity of 78.25%.

MAIA Biotechnology has a consensus price target of $12.14, signalling upside risk potential of 581.74%. On the other hand Eli Lilly and has an analysts' consensus of $952.27 which suggests that it could grow by 25.05%. Given that MAIA Biotechnology has higher upside potential than Eli Lilly and, analysts believe MAIA Biotechnology is more attractive than Eli Lilly and.

MAIA Biotechnology has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Eli Lilly and has a beta of 0.405, suggesting its less volatile than the S&P 500 by 59.528%.

MAIA Biotechnology has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly and offers a yield of 0.74% to investors and pays a quarterly dividend of $1.50 per share. MAIA Biotechnology pays -- of its earnings as a dividend. Eli Lilly and pays out 44.2% of its earnings as a dividend. Eli Lilly and's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

MAIA Biotechnology quarterly revenues are --, which are smaller than Eli Lilly and quarterly revenues of $12.7B. MAIA Biotechnology's net income of -$4.5M is lower than Eli Lilly and's net income of $2.8B. Notably, MAIA Biotechnology's price-to-earnings ratio is -- while Eli Lilly and's PE ratio is 61.96x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for MAIA Biotechnology is -- versus 14.04x for Eli Lilly and. Usually stocks with elevated PS ratios are considered overvalued.

Merck & has a net margin of -- compared to MAIA Biotechnology's net margin of 32.71%. MAIA Biotechnology's return on equity of -- beat Merck &'s return on equity of 39.02%.

MAIA Biotechnology has a consensus price target of $12.14, signalling upside risk potential of 581.74%. On the other hand Merck & has an analysts' consensus of $101.79 which suggests that it could grow by 24.86%. Given that MAIA Biotechnology has higher upside potential than Merck &, analysts believe MAIA Biotechnology is more attractive than Merck &.

MAIA Biotechnology has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Merck & has a beta of 0.389, suggesting its less volatile than the S&P 500 by 61.063%.

MAIA Biotechnology has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Merck & offers a yield of 3.93% to investors and pays a quarterly dividend of $0.81 per share. MAIA Biotechnology pays -- of its earnings as a dividend. Merck & pays out 45.8% of its earnings as a dividend. Merck &'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

MAIA Biotechnology quarterly revenues are --, which are smaller than Merck & quarterly revenues of $15.5B. MAIA Biotechnology's net income of -$4.5M is lower than Merck &'s net income of $5.1B. Notably, MAIA Biotechnology's price-to-earnings ratio is -- while Merck &'s PE ratio is 11.87x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for MAIA Biotechnology is -- versus 3.24x for Merck &. Usually stocks with elevated PS ratios are considered overvalued.

Regeneron Pharmaceuticals has a net margin of -- compared to MAIA Biotechnology's net margin of 26.7%. MAIA Biotechnology's return on equity of -- beat Regeneron Pharmaceuticals's return on equity of 15.7%.

MAIA Biotechnology has a consensus price target of $12.14, signalling upside risk potential of 581.74%. On the other hand Regeneron Pharmaceuticals has an analysts' consensus of $728.55 which suggests that it could grow by 32.46%. Given that MAIA Biotechnology has higher upside potential than Regeneron Pharmaceuticals, analysts believe MAIA Biotechnology is more attractive than Regeneron Pharmaceuticals.

MAIA Biotechnology has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Regeneron Pharmaceuticals has a beta of 0.325, suggesting its less volatile than the S&P 500 by 67.458%.

MAIA Biotechnology has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Regeneron Pharmaceuticals offers a yield of 0.32% to investors and pays a quarterly dividend of $0.88 per share. MAIA Biotechnology pays -- of its earnings as a dividend. Regeneron Pharmaceuticals pays out -- of its earnings as a dividend.

MAIA Biotechnology quarterly revenues are --, which are smaller than Regeneron Pharmaceuticals quarterly revenues of $3B. MAIA Biotechnology's net income of -$4.5M is lower than Regeneron Pharmaceuticals's net income of $808.7M. Notably, MAIA Biotechnology's price-to-earnings ratio is -- while Regeneron Pharmaceuticals's PE ratio is 14.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for MAIA Biotechnology is -- versus 4.46x for Regeneron Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.